Skip to content

XOMA Corporation XOMA Contingent Value Rights Liability Working Capital Adjustment

Contingent Value Rights Liability Working Capital Adjustment at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
-$624K+66.8%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-$968K+80.1%
Innospec logo
InnospecIOSP
-$4.7M-771%
Core Scientific, Inc. logo
Core Scientific, Inc.CORZ
-$1.04M-108%
PVL
Palvella TherapeuticsPVLA
$202K
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-$968K+80.1%

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$746.04M+159%
Enterprise value$785.17M+152%
P/E22.1×
P/S15.4×+8.7×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Reported directly by XOMA Corporation in its filing.

Tagged under the XBRL concept xoma:ContingentValueRightsLiabilityWorkingCapitalAdjustment.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's contingent value rights liability working capital adjustment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's contingent value rights liability working capital adjustment?
XOMA Corporation (XOMA) reported contingent value rights liability working capital adjustment of -$131K in Q1 2026.
How has XOMA Corporation's contingent value rights liability working capital adjustment changed year-over-year?
XOMA Corporation's contingent value rights liability working capital adjustment decreased by 233.0% year-over-year, from $98.5K to -$131K.
What does contingent value rights liability working capital adjustment mean?
Represents adjustments to working capital related to the valuation of contingent value rights (CVRs) issued as part of acquisition agreements. This reflects the expected future cash obligations tied to specific clinical or commercial milestones of therapeutic candidates. It is a key indicator of potential future cash outflows linked to the success of the royalty portfolio.